A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Entinostat (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors Syndax Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 12 Apr 2018 Status changed from recruiting to completed.
- 07 Aug 2017 Status changed from not yet recruiting to recruiting.